Home > Information > News

Cardiovascular minimally invasive company completes $380 million in Series E funding! Aiding the commercialization of the Carillon mitral valve repair system

Medical polymer materials 2025-03-24 15:28:01

Recently, Cardiac Dimensions announced the completion of a $53 million (approximately 383 million RMB) oversubscribed Series E financing round, led by Ally Bridge Group, with participation from new investor Claret Capital Partners and significant support from existing investors.

The company designed the Carillon system, which aims to restore natural mitral valve function without damaging the mitral valve leaflets. The company plans to use these funds to complete a pivotal study of the Carillon system in the United States and to support the commercialization of the system.

product information

The Carillon mitral contour system is the only indirect, non-contact mitral valve repair solution that can treat patients with mitral regurgitation grades of 2+, 3+, and 4+, producing an annuloplasty effect while initiating left ventricular remodeling and improving long-term survival rates for patients.

The Carillon system consists of an implant and a delivery system. The implant adopts a shape similar to the coronary sinus, with a band connecting the proximal anchor and the distal anchor. This shaping band utilizes the venous anatomy of the heart to secure the mitral valve apparatus. The implant can be delivered to the fixation position via a right heart approach using the delivery system.

Implantation method: Transcatheter implantation through a small incision in the neck to access the jugular vein, delivering the device to the optimal position in the coronary sinus without general anesthesia.

product advantages

Short path: The approach from the jugular vein through the right heart system is shorter, with an implantation time of about 1 hour.
Easy to operate: The technical difficulty of percutaneous catheter surgery implantation is low, easy to operate, and has a short learning cycle.
does not affect subsequent surgeries: as an indirect, non-contact mitral valve repair device, it does not affect the operation of other subsequent heart failure surgeries, and can be removed if necessary.

Cardiac Dimensions

Cardiac Dimensions, headquartered in Kirkland, Washington, USA, is dedicated to developing novel interventional therapy tools for the treatment of heart failure and mitral regurgitation-related conditions.

The company's representative product, the Carillon contour system, is a groundbreaking non-surgical device developed for the treatment of functional mitral regurgitation. Their system uses a catheter-based approach to reshape the mitral valve and reduce mitral regurgitation.

According to the data from Crunchbase, the company has previously completed 10 rounds of financing, with total funds raised exceeding $200 million:

【Copyright and Disclaimer】The above information is collected and organized by PlastMatch. The copyright belongs to the original author. This article is reprinted for the purpose of providing more information, and it does not imply that PlastMatch endorses the views expressed in the article or guarantees its accuracy. If there are any errors in the source attribution or if your legitimate rights have been infringed, please contact us, and we will promptly correct or remove the content. If other media, websites, or individuals use the aforementioned content, they must clearly indicate the original source and origin of the work and assume legal responsibility on their own.

Cardiovascular minimally invasive company completes $380 million in Series E funding! Aiding the commercialization of the Carillon mitral valve repair system

Most Popular